Optimal timing for hepatitis C therapy in US patients eligible for liver transplantation: a cost-effectiveness analysis

Alimentary Pharmacology and Therapeutics

Volumn 44, Issue 10, 2016, Pages 1090-1101

  Njei, B ^a   McCarty, T R ^a   Fortune, B E ^a   Lim, J K ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LEDIPASVIR PLUS SOFOSBUVIR; RIBAVIRIN; ANTIVIRUS AGENT; BENZIMIDAZOLE DERIVATIVE; FLUORENE DERIVATIVE; LEDIPASVIR; SOFOSBUVIR;

ARTICLE; CHILD PUGH SCORE; CLINICAL TRIAL (TOPIC); COST EFFECTIVENESS ANALYSIS; DECOMPENSATED LIVER CIRRHOSIS; HEPATITIS C; HEPATITIS C VIRUS GENOTYPE 1; HEPATITIS C VIRUS GENOTYPE 4; HUMAN; LIVER CELL CARCINOMA; LIVER TRANSPLANTATION; LIVING DONOR; MODEL FOR END STAGE LIVER DISEASE SCORE; MONTE CARLO METHOD; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; RECURRENT INFECTION; UNITED STATES; CARCINOMA, HEPATOCELLULAR; COMBINATION DRUG THERAPY; COST BENEFIT ANALYSIS; DISEASE COURSE; ECONOMICS; GENETICS; GENOTYPE; HEPACIVIRUS; LIVER CIRRHOSIS; LIVER NEOPLASMS; TUMOR RECURRENCE;

ANTIVIRAL AGENTS; BENZIMIDAZOLES; CARCINOMA, HEPATOCELLULAR; COST-BENEFIT ANALYSIS; DISEASE PROGRESSION; DRUG THERAPY, COMBINATION; FLUORENES; GENOTYPE; HEPACIVIRUS; HEPATITIS C; HUMANS; LIVER CIRRHOSIS; LIVER NEOPLASMS; LIVER TRANSPLANTATION; NEOPLASM RECURRENCE, LOCAL; QUALITY-ADJUSTED LIFE YEARS; RIBAVIRIN; SOFOSBUVIR; UNITED STATES;

EID: 84994850924     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/apt.13798     Document Type: Article

References (58)

1. Viral Hepatitis - Statistics & Survelliance. CDC – Centers for Disease Control and Prevention. Available at: http://www.cdc.gov/hepatitis/statistics/incidencearchive.htm (accessed 1 February 2016).
2. Rein DB, Borton J, Liffmann DK, Wittenborn JS. The burden of hepatitis C to the United States medicare system in 2009: descriptive and economic characteristics. Hepatology 2016; 63: 1135–44.
3. Alberti A, Vario A, Ferrari A, Pistis R. Review article: chronic hepatitis C – natural history and cofactors. Aliment Pharmacol Ther 2005; 22(Suppl. 2): 74–8.
4. Wong RJ, Aguilar M, Cheung R, et al. Nonalcoholic steatohepatitis is the second leading etiology of liver disease among adults awaiting liver transplantation in the United States. Gastroenterology 2015; 148: 547–55.
5. Davis GL, Albright JE, Cook SF, Rosenberg DM. Projecting future complications of chronic hepatitis C in the United States. Liver Transpl 2003; 9: 331–8.
6. Gane EJ, Agarwal K. Directly acting antivirals (DAAs) for the treatment of chronic hepatitis C virus infection in liver transplant patients: “a flood of opportunity”. Am J Transplant 2014; 14: 994–1002.
7. Miller MH, Agarwal K, Austin A, et al. Review article: 2014 UK consensus guidelines – hepatitis C management and direct-acting anti-viral therapy. Aliment Pharmacol Ther 2014; 39: 1363–75.
8. Backus LI, Belperio PS, Shahoumian TA, Loomis TP, Mole LA. Comparative effectiveness of ledipasvir/sofosbuvir +/- ribavirin vs. ombitasvir/paritaprevir/ritonavir + dasabuvir +/- ribavirin in 6961 genotype 1 patients treated in routine medical practice. Aliment Pharmacol Ther 2016; 44: 400–10.
9. Pacholczyk M, Lagiewska B, Lisik W, et al. Liver transplantation for HCV cirrhosis; cautious optimism after 10 years of experience. Ann Transplant 2012; 17: 5–10.
10. Berenguer M, Prieto M, Rayon JM, et al. Natural history of clinically compensated hepatitis C virus-related graft cirrhosis after liver transplantation. Hepatology 2000; 32: 852–8.
11. Charlton M, Ruppert K, Belle SH, et al. Long-term results and modeling to predict outcomes in recipients with HCV infection: results of the NIDDK liver transplantation database. Liver Transplant 2004; 10: 1120–30.
12. Forman LM, Lewis JD, Berlin JA, Feldman HI, Lucey MR. The association between hepatitis C infection and survival after orthotopic liver transplantation. Gastroenterology 2002; 122: 889–96.
13. Wright TL, Donegan E, Hsu HH, et al. Recurrent and acquired hepatitis C viral infection in liver transplant recipients. Gastroenterology 1992; 103: 317–22.
14. Fortune BE, Martinez-Camacho A, Kreidler S, Gralla J, Everson GT. Post-transplant survival is improved for hepatitis C recipients who are RNA negative at time of liver transplantation. Transplant Int 2015; 28: 980–9.
15. Moreno Planas JM, Rubio Gonzalez E, Boullosa Grana E, et al. Peginterferon and ribavirin in patients with HCV cirrhosis after liver transplantation. Transplant Proc 2005; 37: 2207–8.
16. Dumortier J, Scoazec JY, Chevallier P, Boillot O. Treatment of recurrent hepatitis C after liver transplantation: a pilot study of peginterferon alfa-2b and ribavirin combination. J Hepatol 2004; 40: 669–74.
17. Rodriguez-Luna H, Khatib A, Sharma P, et al. Treatment of recurrent hepatitis C infection after liver transplantation with combination of pegylated interferon alpha2b and ribavirin: an open-label series. Transplantation 2004; 77: 190–4.
18. Mukherjee S, Rogge J, Weaver L, Schafer DF. Pilot study of pegylated interferon alfa-2b and ribavirin for recurrent hepatitis C after liver transplantation. Transplant Proc 2003; 35: 3042–4.
19. Neff GW, Montalbano M, O'Brien CB, et al. Treatment of established recurrent hepatitis C in liver-transplant recipients with pegylated interferon-alfa-2b and ribavirin therapy. Transplantation 2004; 78: 1303–7.
20. Neumann U, Puhl G, Bahra M, et al. Treatment of patients with recurrent hepatitis C after liver transplantation with peginterferon alfa-2B plus ribavirin. Transplantation 2006; 82: 43–7.
21. Chalasani N, Manzarbeitia C, Ferenci P, et al. Peginterferon alfa-2a for hepatitis C after liver transplantation: two randomized, controlled trials. Hepatology 2005; 41: 289–98.
22. Angelico M, Petrolati A, Lionetti R, et al. A randomized study on Peg-interferon alfa-2a with or without ribavirin in liver transplant recipients with recurrent hepatitis C. J Hepatol 2007; 46: 1009–17.
23. Curry MP, Forns X, Chung RT, et al. Sofosbuvir and ribavirin prevent recurrence of HCV infection after liver transplantation: an open-label study. Gastroenterology 2015; 148: 100–7.e1.
24. Walker DR, Pedrosa MC, Manthena SR, Patel N, Marx SE. Early view of the effectiveness of new direct-acting antiviral (DAA) regimens in patients with hepatitis C virus (HCV). Adv Ther 2015; 32: 1117–27.
25. Cortesi PA, Mantovani LG, Ciaccio A, et al. Cost-effectiveness of new direct-acting antivirals to prevent post-liver transplant recurrent hepatitis. Am J Transplant 2015; 15: 1817–26.
26. Weinstein MC, Siegel JE, Gold MR, Kamlet MS, Russell LB. Recommendations of the panel on cost-effectiveness in health and medicine. JAMA 1996; 276: 1253–8.
27. Charlton M, Everson GT, Flamm SL, et al. Ledipasvir and sofosbuvir plus ribavirin for treatment of HCV infection in patients with advanced liver disease. Gastroenterology 2015; 149: 649–59.
28. 2015 annual report of the U.S. Organ Procurement and Transplantation Network and the Scientific Registry of Transplant Recipients: Transplant Data 2006-2015. Department of Health and Human Services, Health Resources and Services Administration, Healthcare Systems Bureau, Division of Transplantation, Rockville, MD; United Network for Organ Sharing, Richmond, VA.
29. Alberti A, Chemello L, Benvegnu L. Natural history of hepatitis C. J Hepatol 1999; 31(Suppl. 1): 17–24.
30. Alawazi W, Cunningham M, Dearden J, Foster GR. Systematic review: outcome of compensated cirrhosis due to chronic hepatitis C infection. Aliment Pharmacol Ther 2013; 32: 344–55.
31. Sweeting MJ, de Angelis D, Neal KR, et al. Estimated progression rates in three United Kingdom hepatitis C cohorts differed according to method of recruitment. J Clin Epidemiol 2006; 59: 144–52.
32. Saab S, Hunt DR, Stone MA, McClune A, Tong MJ. Timing of hepatitis C antiviral therapy in patients with advanced liver disease: a decision analysis model. Liver Transplant 2010; 16: 748–59.
33. Hutchinson SJ, Bird SM, Goldberg DJ. Modeling the current and future disease burden of hepatitis C among injection drug users in Scotland. Hepatology 2005; 42: 711–23.
34. Italian National Transplant Center - Ststema Informativo Trapianto. Available at: https//trapianti.sanita.it/statsiche/home.asp (accessed February 13, 2016).
35. Cadahia V, Gonzalez-Dieguez ML, Alonso P, et al. Exclusions and deaths on the liver transplant waiting list. Transpl Proc 2010; 42: 622–4.
36. Prieto M, Berenguer M, Rayon JM, et al. High incidence of allograft cirrhosis in hepatitis C virus genotype 1b infection following transplantation: relationship with rejection episodes. Hepatology 1999; 29: 250–6.
37. Angelico M, Cillo U, Fagiuoli S, et al. Liver match, a prospective observational cohort study on liver transplantation in Italy: study design and current practice of donor-recipient matching. Dig Liver Dis 2011; 43: 155–64.
38. Trotter JF, Osborne JC, Heller M, Christians U. Effect of hepatitis C infection on tacrolimus doses and blood levels in liver transplantation recipients. Aliment Pharmacol Ther 2005; 22: 37–44.
39. Logge C, Vettorazzi E, Fischer L, Nashan B, Sterneck M. Cost-effectiveness analysis of antiviral treatment in liver transplant recipients with HCV infection. Transplant Int 2013; 26: 527–34.
40. Siebert U, Sroczynski G, Aidelsburger P, et al. Clinical effectiveness and cost effectiveness of tailoring chronic hepatitis C treatment with peginterferon alpha-2b plus ribavirin to HCV genotype and early viral response: a decision analysis based on German guidelines. Pharmacoeconomics 2009; 27: 341–54.
41. Coffin PO, Scott JD, Golden MR, Sullivan SD. Cost-effectiveness and population outcomes of general population screening for hepatitis C. Clin Infect Dis 2012; 54: 1259–71.
42. Zhang S, Bastian ND, Griffin PM. Cost-effectiveness of sofosbuvir-based treatments for chronic hepatitis C in the US. BMC Gastroenterol 2015; 15: 98.
43. Younossi ZM, Singer ME, McHutchison JG, Shermock KM. Cost effectiveness of interferon alpha2b combined with ribavirin for the treatment of chronic hepatitis C. Hepatology 1999; 30: 1318–24.
44. Ciampichini R, Fagiuoli S, Scalone L, et al. Societal burden in hepatitis C patients: the COME study results. Value Health 2012; 15: A138.
45. Conferenza delle regioni e delle province autonome 12/41/cr05a/c7 – Accordo interregionale per la compensazione della mobilita sanitaria. Available at: http://www.sanita.ilsole24ore.com/pdf_2010/Sanita2/_Oggetti_Correlati/Documenti/Regioni-e-Aziende/TUC_2012.pdf?uuid=5c5fbc90-a757-11e2-82ba-89cca4ad5083 (accessed February 15, 2016).
46. CPI Inflation Calculator. United States Deparment of Labor: Bureau of Labor Statistics. Available at: http://www.bls.gov/data/inflation_calculator.htm (accessed 4 February 2016).
47. Beck JR, Pauker SG, Gottlieb JE, Klein K, Kassirer JP. A convenient approximation of life expectancy (the “DEALE”). II. Use in medical decision-making. Am J Med 1982; 73: 889–97.
48. Neumann PJ, Cohen JT, Weinstein MC. Updating cost-effectiveness – the curious resilience of the $50,000-per-QALY threshold. N Engl J Med 2014; 371: 796–7.
49. Chak E, Talal AH, Sherman KE, Schiff ER, Saab S. Hepatitis C virus infection in USA: an estimate of true prevalence. Liver Int 2011; 31: 1090–101.
50. Mancuso A. Letter: why treatments of hepatitis C virus are less effective in cirrhosis. Aliment Pharmacol Ther 2015; 41: 707.
51. Chidi AP, Rogal S, Bryce CL, et al. Cost-effectiveness of new antiviral regimens for treatment-naive U.S. veterans with hepatitis C. Hepatology 2016; 63: 428–36.
52. Younossi ZM, Park H, Saab S, Ahmed A, Dieterich D, Gordon SC. Cost-effectiveness of all-oral ledipasvir/sofosbuvir regimens in patients with chronic hepatitis C virus genotype 1 infection. Aliment Pharmacol Ther 2015; 41: 544–63.
53. Younossi Z, Henry L. Systematic review: patient-reported outcomes in chronic hepatitis C – the impact of liver disease and new treatment regimens. Aliment Pharmacol Ther 2015; 41: 497–520.
54. Chhatwal J, Kanwal F, Roberts MS, Dunn MA. Cost-effectiveness and budget impact of hepatitis C virus treatment with sofosbuvir and ledipasvir in the United States. Ann Intern Med 2015; 162: 397–406.
55. Leidner AJ, Chesson HW, Spradling PR, Holmberg SD. Assessing the Effect of Potential Reductions in Non-Hepatic Mortality on the Estimated Cost-Effectiveness of Hepatitis C Treatment in Early Stages of Liver Disease. Appl Health Econ Health Policy 2016. [Epub ahead of print].
56. Saab S, Gordon SC, Park H, Sulkowski M, Ahmed A, Younossi Z. Cost-effectiveness analysis of sofosbuvir plus peginterferon/ribavirin in the treatment of chronic hepatitis C virus genotype 1 infection. Aliment Pharmacol Ther 2014; 40: 657–75.
57. Ellingson K, Seem D, Nowicki M, Strong DM, Kuehnert MJ, Organ Procurement Organization Nucleic Acid Testing Yield Project T. Estimated risk of human immunodeficiency virus and hepatitis C virus infection among potential organ donors from 17 organ procurement organizations in the United States. Am J Transplant 2011; 11: 1201–8.
58. Coilly A, Samuel D. Pros and cons: usage of organs from donors infected with hepatitis C virus – revision in the direct-acting antiviral era. J Hepatol 2016; 64: 226–31.